# Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

> **NCT02304081** · PHASE4 · COMPLETED · sponsor: **Prof. Dr. Thomas Forst** · enrollment: 64 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Placebo for Saxagliptin

## Key facts

- **NCT ID:** NCT02304081
- **Lead sponsor:** Prof. Dr. Thomas Forst
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02304081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02304081, "Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02304081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*